85. 特発性間質性肺炎 Idiopathic interstitial pneumonia Clinical trials / Disease details

臨床試験数 : 598 / 薬物数 : 435 - (DrugBank : 116) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 210

3 trials found

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02036580 (ClinicalTrials.gov)	January 2014	13/1/2014	D2212C00002 J-Phase II Study	A Phase 2, Multicenter, Double-Blind Within Cohort, Dose-escalation Study to Evaluate the Safety and ...	Idiopathic Pulmonary Fibrosis	Biological: tralokinumab cohort 1;Biological: tralokinumab cohort 2;Other: Placebo	AstraZeneca	MedImmune LLC	Completed	50 Years	N/A	All	37	Phase 2	Japan
2	NCT01629667 (ClinicalTrials.gov)	October 2012	12/6/2012	A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumabin Adults With Idio ...	A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumabin Adults With Idio ...	Idiopathic Pulmonary Fibrosis	Biological: Tralokinumab;Other: Placebo	MedImmune LLC	NULL	Terminated	50 Years	79 Years	All	409	Phase 2	United States;Australia;Canada;Israel;Korea, Republic of;Peru
3	JPRN-JapicCTI-142452		21/02/2014	A Phase 2, Multicenter, Double-Blind Within Cohort, Dose-escalation Study to Evaluate the Safety and ...	A Phase 2, Multicenter, Double-Blind Within Cohort, Dose-escalation Study to Evaluate the Safety and ...	Idiopathic Pulmonary Fibrosis	Intervention name : Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass tha ...	AstraZeneca	MedImmune LLC		50		BOTH		Phase 2	NULL

First Previous1Next Last